bi 11634
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT02214914)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor XINHIBITOR
F10 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 11634
- bi 11634
- bi 11634
- n-(1-(5-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl)-3-methyl-4-(3-oxo-4-morpholinyl)benzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02214953 | Phase 1 | Oct 1, 2007 | Boehringer Ingelheim |
| NCT02214940 | Phase 1 | Jun 1, 2007 | Boehringer Ingelheim |
| NCT02214927 | Phase 1 | May 1, 2007 | Boehringer Ingelheim |
| NCT02214914 | Phase 1 | Nov 1, 2006 | Boehringer Ingelheim |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 4 | 4 | 1 | 2006 |
1 organizations
Page 1 / 1